Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Astellas Pharma Ltd
3rd Floor, Future House, The Glanty, Egham, Surrey, TW20 9AH
Telephone: +44 (0)1784 419615
Fax: +44 (0)1784 419583
Medical Information Direct Line: 0800 783 5018
Medical Information e-mail: medinfo@gb.astellas.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 13/04/2011
SPC De-Noltab


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

DE-NOLTAB


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Tri-potassium di-citrato bismuthate equivalent to 120mg Bi2O3


Go to top of the page
3. PHARMACEUTICAL FORM

Film-coated tablet


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of gastric and duodenal ulcers.


Go to top of the page
4.2 Posology and method of administration

For Adults, and the Elderly:

One tablet to be taken four times a day, half an hour before each of the three main meals and two hours after the last meal of the day, or

Two tablets to be taken twice daily, half an hour before breakfast and half an hour before the evening meal, or

As directed by the physician

The maximum duration for one course of treatment is two months; De-Noltab should not be used for maintenance therapy.

For children:

Not recommended.


Go to top of the page
4.3 Contraindications

In cases of severe renal insufficiency.

Harmful to people on a low potassium diet.

Hypersensitivity to the active substance(s) or to any of the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Prolonged use of high doses of bismuth compounds is not recommended because this has occasionally led to reversible encephalopathy. It is, not advisable to take other bismuth-containing drugs concomitantly.

Contains approximately 2 mmol (approximately 40 mg) potassium per tablet. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No other medicines, food or drink, in particular antacids, milk, fruit or fruit juices, should be consumed within half an hour before or after a dose of De-Nol as they may influence its effect. The efficacy of oral tetracyclines may be inhibited.


Go to top of the page
4.6 Pregnancy and lactation

On theoretical grounds De-Noltab is contraindicated in pregnancy. No information is available on excretion in breast milk.


Go to top of the page
4.7 Effects on ability to drive and use machines

None reported.


Go to top of the page
4.8 Undesirable effects

System Organ Class

Common

>1/100, <1/10

Uncommon

1/1000, <1/100

Very rare

<1/10,000, Not known (cannot be estimated from the available data)

Immune system disorders

  

anaphylactic reaction

Gastrointestinal disorders

blackening of the stool

nausea, vomiting, constipation, diarrhoea

 

Skin and subcutaneous tissue disorders

 

rash, pruritus

 


Go to top of the page
4.9 Overdose

Extremely few cases of overdosage have been reported; contact the company for further information.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The active constituent exerts a local healing effect at the ulcer site, and by eradication or reduction of Helicobacter pylori defers relapse.


Go to top of the page
5.2 Pharmacokinetic properties

The action is local in the gastro-intestinal tract.


Go to top of the page
5.3 Preclinical safety data

No relevant pre-clinical safety data has been generated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Povidone K 30

Polacrillin potassium

Macrogol 6000

Magnesium stearate

Maize starch

Hypromellose


Go to top of the page
6.2 Incompatibilities

None


Go to top of the page
6.3 Shelf life

Four years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C


Go to top of the page
6.5 Nature and contents of container

Amber glass bottles and/or aluminium foil strips, containing 112 tablets


Go to top of the page
6.6 Special precautions for disposal and other handling

None


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Astellas Pharma Ltd.

3rd Floor

Future House

The Glanty

Egham

Surrey

TW20 9AH

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL0166/0124


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1 December 1986;11th January 2007.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

13th December 2010


Go to top of the page
11. LEGAL CATEGORY

P



More information about this product

  • Patient Information Leaflets (PILs):

    De-Noltab

  • Alternative format Patient Information Leaflets (X-PILs):

    De-Noltab

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/2254/SPC/


Active Ingredients/Generics

 
  tri-potassium di-citrato bismuthate